ArticleAntonie van Leeuwenhoek2025
Harnessing the antimicrobial, antibiofilm, and antioxidant activities of Cinnamomum verum J. Presl essential oil against Aeromonas spp.
Article in Antonie van Leeuwenhoek, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aeromonas spp. are associated with significant mortalities of economically important Channa striata. Antibiotic resistance and biofilm-forming capacity make them difficult to eradicate from the environment, and studies on antibiotics alternatives, such as Cinnamomum verum essential oil (CVO), in aquaculture are scarce. This study aims to characterise the phytochemicals of CVO and to investigate its in-vitro antibacterial, antibiofilm, and antioxidant potency against A. hydrophila and A. jandaei, isolated from diseased C. striata. The CVO was extracted from the bark of C. verum via hydrodistillation and its characterisation was performed using Gas Chromatography and Mass Spectrometry (GC/MS). The antibacterial potency was evaluated by determination of Zone of Inhibition (ZoI), Minimum Inhibitory Concentration (MIC), Minimum Bactericidal Concentration (MBC), growth kinetics assay, and antibiofilm assay. Additionally, antioxidant activity was analysed via DPPH and ABTS assay as a function of concentration of CVO and respective reference standard. The GC/MS analysis identified twelve compounds (89.85%), with E-cinnamaldehyde (42.735%) and Eugenol (18.583%) as the predominant compounds. Antibacterial assay demonstrated higher sensitivity of A. jandaei (maximum ZoI: 29.5 ± 0.50 mm; MIC: 156 µg/ml; MBC: 312.5 µg/ml) than A. hydrophila (maximum ZoI: 25.4± 0.40 mm; MIC: 312.5 µg/ml; MBC: 625 µg/ml). Strong biofilm inhibition potential (> 50%) of CVO was observed against A. hydrophila (range:7.07 ± 4.51% to 74.46 ± 2.12%) and A. jandaei (range:10.80 ± 5.5% to 80.17 ± 4.56%). The IC
Indexed as
Identifiers
41444471What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.